Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data

Christoph Würnschimmel MD1,2 | Mike Wenzel MD, BSc3 | Nuowei Wang1 | Zhe Tian MSc2 | Pierre I. Karakiewicz MD2 | Markus Graefen MD1 | Hartwig Huland MD1 | Derya Tilki MD1,4

1Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
2Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
3Department of Urology, University Hospital Frankfurt, Frankfurt, Germany
4Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Correspondence
Christoph Würnschimmel, MD, Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany. Email: c.wuernschimmel@uke.de

Abstract

Background: To examine overall survival rates within a large cohort of German prostate cancer (PCa) patients and to compare these with life-expectancy (LE) predictions derived from German life tables. We hypothesized that the advantage of good general health in radical prostatectomy (RP) patients combined with favorable cancer outcomes might lead to even higher overall survival rates over 10 years compared to the LE of a general population.

Methods: A total of 6483 patients were treated with RP between 1992 and 2007 at the Martini-Klinik Prostate Cancer Center. Preoperative risk classification was performed according to D’Amico. Postoperative risk classification was performed according to the Cancer of the Prostate Risk Assessment score (CAPRA-S). A simulated cohort was created that resembled the exact age distribution of the RP population using Monte Carlo simulation which was based on data derived from official male German life tables (1992–2017). Markov chain was used to represent natural age progression of the simulated cohort. Kaplan–Meier plots were created to display the differences between 10-year observed overall survival (OS) and the simulated, predicted LE.

Results: For D’Amico low risk and intermediate risk, 10-year OS was 12.0% and 9.2% above predicted LE in the simulated cohort, respectively. For D’Amico high risk, OS was virtually the same as predicted LE (0.8% difference in favor of RP treated patients). For CAPRA-S low and intermediate risk, OS was 11.8% and 9.7% above predicted LE. For CAPRA-S high risk, OS was virtually the same as predicted LE (0.3% difference in favor of the simulated cohort).

Conclusions: Low- and intermediate risk PCa patients treated with RP can expect a very favorable overall survival, that even exceeds LE predictions. High risk patients’ overall survival perfectly aligns with LE predictions.

Keywords
life table, life-expectancy, prostate cancer, radical prostatectomy, survival
1 | INTRODUCTION

Excellent curative management options for prostate cancer (PCa) are available and a large part of treated patients can expect a favorable oncological outcome. For the near future, a further increase of long-term survival rates after active treatment in PCa patients is expected. However, since PCa is more common in the elderly population, and furthermore, usually progresses at slower rates compared to other malignancies, patient age and estimated life-expectancy (LE) are important factors that have to be taken into consideration in the clinical decision-making process. Patients with a long LE can expect to benefit most from active treatment, while patients with a short LE may benefit less, or even may not benefit at all. Therefore, when deciding for active treatment, a LE of over 10 years is deemed necessary. In this regard, one of the advocated European Association of Urology (EAU) guideline recommendations is the use of life tables to evaluate the patients' LE. Without taking into account individual comorbidities or other health-related assessments, life tables are suitable to narrow down the estimated LE, since they resemble national population samples. Radical prostatectomy (RP) is an invasive approach, that is usually more frequently performed in patients with a good general health, as opposed to patients treated with other, less invasive methods. Therefore, RP treated patients may represent a population that exhibits more favorable health compared to individuals of same age within a general population. This may ultimately translate into higher overall survival rates compared to life tables' derived LE predictions. We tested this hypothesis in German PCa patients treated with RP in a center of excellence and compared survival rates to corresponding German life tables.

2 | PATIENTS AND METHODS

After approval of the institutional review board, we identified 7012 PCa patients in our institutional database who received RP, with or without pelvic lymph node dissection (PLND), between 1992 and 2007. We excluded 261 patients with pathological T-stage 4 (pT4) and/or distant metastasis (M1). Furthermore, 268 patients with missing or inconclusive pT-stage, Gleason grade groups (GGG), missing patient age or missing follow-up data were excluded. After applying these exclusion criteria, a total of 6483 patients were included in this retrospective single-center study. All RP's and PLND's were performed by staff urologists in a standardized manner, as previously described. Dedicated uro-pathologists assessed all specimen and reported pathological results according to the Gleason System and the TNM classification. Preoperative risk classification was performed according to D'Amico low, intermediate and high risk groups. Postoperative risk classification was performed according to the Cancer of the Prostate Risk Assessment score (CAPRA-S). CAPRA-S scores were further by stratified by low- (CAPRA-S 0–2), intermediate- (CAPRA-S 3–5), and high (CAPRA-S 6 or more) risk of recurrence.

2.1 | Statistical analyses

Univariable Kaplan-Meier plots were created to illustrate observed overall survival (OS) outcomes over 10 years. Furthermore, Monte Carlo simulation was performed to create a simulated cohort that resembled the exact age composition of the RP-treated population, according to previous methodology. Using official male German life table data from the years 1992 to 2017, a Markov chain representing natural age progression for the simulated cohort was computed, in which each simulated patient could either survive or die within each of the 10 simulated year intervals. Consequently, the model computed a 10-year LE prediction for a simulated cohort that was based on the exact ages of actual RP treated patients. The predicted LE of the simulated cohort was then included in Kaplan-Meier plots and compared with OS rates. R software environment for statistical computing and graphics (version 3.4.0 for MAC OS X; http://www.r-project.org/) was used for all statistical analyses. Descriptive statistics included frequencies and proportions for categorical variables. Medians and interquartile ranges (IQR) were reported for continuously coded variables. The χ² and Log-rank tested the statistical significance in proportions and survival differences. All tests were two-sided with a level of significance set at p < .05.

3 | RESULTS

Median follow-up was 144 months (IQR: 92.5–180.10). Median age of the overall cohort was 63 years (IQR: 59–67). Considering preoperative patient characteristics, D'Amico low (38.7%) and intermediate (36.9%) risk groups were predominantly exhibited in the overall cohort. Considering postoperative patient characteristics, the majority of patients (58.3%) exhibited a low risk of recurrence, as determined by a score of 0–2 in the CAPRA-S.

3.1 | Survival analyses according to preoperative characteristics

When taking into account the overall population of 6483 RP treated patients between 1992 and 2017, regardless of risk stratification, OS at 10 years was 90.7%. For this population, a simulated cohort of 6483 patients was created, that exactly resembled the age distribution of the real cohort. For this simulated cohort, predicted LE for 10 years was 81.2%. Therefore, the calculated difference between OS and predicted LE was 9.5%, in favor of RP treated patients (Figure 1). The more favorable OS of RP treated patients was also exhibited when stratifying the overall cohort into two different age subgroups according to overall median age at diagnosis (63 years). In these analyses, in the subgroup of patients aged 63 or younger as well as in the subgroup of patients over 63 years, a more favorable OS than predicted by LE was recorded. However, the older subgroup exhibited larger differences between OS and predicted LE at...
10 years than their younger counterparts (15.5% difference for the subgroup of patients over 63 years and 5.9% for the subgroup of patients aged 63 years or younger, Figure S1). To complement the age-stratified analyses, we also performed a further analysis only relying on D’Amico intermediate risk patients. Here, the difference between OS and predicted LE was also larger in the older subgroup. Specifically, for patients aged 63 years or younger, the difference between OS and predicted LE was 4.6%, in favor of RP treated patients, while for patients over 63 years, the difference was 13.8%, also in favor of RP.

In the next step of the analyses, differences between OS and predicted LE stratified by D’Amico risk groups were calculated, following the same methodology in 5420 patients with complete preoperative tumor information (Figure 2). For D’Amico low risk patients (n = 2508), OS at 10 years was 93.2% compared to a predicted LE of 81.2%, which resulted in a difference of 12.0%, in favor of RP treated patients. For D’Amico intermediate risk patients (n = 2395), OS at 10 years was 89.8% compared to a predicted LE of 80.6%, which resulted in a difference of 9.2%, in favor of RP treated patients. For D’Amico high risk patients (n = 517), OS at 10 years was 82.6% compared to a predicted LE of 81.8%, which resulted in a difference of 0.8%, in favor of RP treated patients (Table 1).

3.2 Survival analyses according to postoperative characteristics

In the next step of the analyses, postoperative tumor characteristics were stratified by CAPRA-S score in 6279 patients with complete postoperative data. For individual CAPRA-S scores, OS compared to respective predicted LE at 10 years was always above predicted LE in all scores from 0 to 6. From a CAPRA-S score of 7 and onwards, OS rates were always beneath predicted LE, with a maximum negative difference of 15.4% for patients with a CAPRA-S score of 9 or higher (Table 2). Thereafter, CAPRA-S was grouped by scores from 0 to 2 (low risk for recurrence, n = 3779), 3 to 5 (intermediate risk for recurrence, n = 1752), and 6 or more (high risk for recurrence, n = 766). OS and respective predicted LE for these groupings were plotted (Figure 3) and differences at 10 years were calculated.

Specifically, for CAPRA-S low risk, OS at 10 years was 93.1% and predicted LE was 81.3%, which resulted in a difference of 11.8% in favor of RP treated patients. For CAPRA-S intermediate risk patients, OS at 10 years was 90.9% and predicted LE was 81.2%, which resulted in a difference of 9.7%, in favor of RP treated patients. For CAPRA-S high risk patients (n = 766), OS at 10 years was 79.1% and predicted LE was 79.4%, which resulted in a difference of 0.3%, in favor of the simulated cohort.

In the final step of the analyses, two subgroups with presumably worst tumor characteristics were identified, and analyses were repeated. The first subgroup consisted of patients with pT3a-b tumor, GGG 4–5 and positive surgical margins. The second subgroup consisted of all pN1 patients. For the first subgroup (Figure 4A, n = 65), OS at 10 years was 56.7% and predicted LE was 81.5%, which resulted in a difference of 24.8% in favor of the simulated cohort. For the second subgroup (Figure 4B, n = 234), OS at 10 years was 71.8% and predicted LE was 82.5%, which resulted in a difference of 10.7% in favor of the simulated cohort.
FIGURE 2  Ten-year observed overall survival rates of D’Amico low-, intermediate- and high-risk prostate cancer patients treated with radical prostatectomy in a single institution between 1992 and 2007 compared to predicted life expectancy from a simulated cohort that resembles exact same age distribution and which is based on German life table data from 1992 to 2017.
DISCUSSION

We assumed that PCa patients treated with RP may represent a selected population that exhibits a favorable general health status, which might even be superior compared to the general population. Based on this assumption, we hypothesized that RP treated patients exhibit higher OS compared to the general population. We tested our hypothesis in RP treated patients at our institution from 1992 to 2007 and compared 10-year OS rates to predicted LE in a simulated cohort model. This model was derived from official German life tables from 1992 to 2017 and was based on the exact same age distribution of the RP treated patients. Our analyses yielded several noteworthy findings.

First, when considering the overall cohort, a higher 10-year OS of RP treated patients was exhibited when compared to the predicted LE of the simulated cohort for the same time period. This survival advantage was in effect from the very beginning of the follow-up and even further increased with longer follow-up time (9.5% survival advantage at 10 years). Furthermore, the OS advantage of RP treated patients compared to predicted LE increased with higher patient age. Specifically, the predicted LE underestimated OS only by 5.9% in patients aged 63 or younger. Conversely, for patients older than 63 years, the predicted LE underestimated OS by 15.5%. This finding implies that the effect of better general health of RP treated patients compared to the German population is indeed even more striking in elderly patients. To account for potential confounding by differences in PCa characteristics between these two artificially created age subgroups of >63 years and ≤63 years, we repeated analyses also in the largest available D'Amico subgroup (intermediate risk). Also in this analysis, virtually the same findings could be encountered, which further strengthens our findings.

Second, the OS advantage of RP treated patients over predicted LE of the is also even more striking in patients with favorable cancer features. For example, when considering preoperative risk stratification using D'Amico risk groups, low risk patients exhibited a survival advantage of 12.0% at 10 years. This survival advantage was also confirmed when considering postoperative risk stratification using CAPRA-S. For CAPRA-S low risk patients, OS exceeded predicted LE of the simulated cohort at 10 years virtually to same extents as seen in D'Amico low risk patients (11.8%).
Third, as opposed to patients with favorable cancer risk features, the observed OS advantage decreased and eventually even ceased to exist in patients with aggressive cancer risk features. While the 10-year OS for D’Amico high risk patients and CAPRA-S high risk patients was at least comparable to the simulated LE of the general population, a certain subgroup of patients fell below the values of the simulated cohort. For example, when considering individual CAPRA-S scores (0–9 or higher) and not per risk group, patients with CAPRA-S score of 7 and onwards always fell below the simulated LE at 10 years by at least 10% and eventually reached a value difference of...
of 15.4% in patients with CAPRA-S score of 9 or higher. Even more distinct survival differences were exhibited when considering a subgroup of patients where highest rates of cancer specific mortality were assumed (pT3a-b, GGG 4–5, positive surgical margin). Ultimately, these patients had the worst OS at 10 years and fell below predicted LE by 24.8%. These findings suggest that the impact of cancer specific mortality in these individuals outweighs other cause mortality, that is often in effect in in RP treated patients.14

Preisser et al. previously demonstrated the feasibility of using life table information to compare OS of a treated population to a simulated cohort based on national population data.7 In their work, North American patients who underwent RP within the Surveillance, Epidemiology and End Results database were compared to Social Security Administration life tables LE estimations. Using this methodology, Preisser et al.8 were the first to report a certain underestimation of predicted LE for RP patients. However, since North American patients cannot be directly compared to European patients, neither in terms of PCa survival nor in general population LE and general health, a separate analysis in European patients was deemed necessary.15–17 To the best of our knowledge, we are the first to use this methodology within a large RP treated, consecutive European PCa cohort. Our findings depict a favorable general health and excellent LE of German patients undergoing RP, which ultimately suggests good patient selection.

In this regard, the EAU and also the German S3 Guidelines recommend to perform active treatment for PCa only in patients with favorable general health and a residual LE of more than 10 years5,18,19. However, since age is not the only prognosticator of survival, further factors should play a role in the assessment of PCa patients. For example, to assess the general health status of elderly patients, the Geriatric-8 assessment tool may be considered.20 Furthermore, the role of comorbidity, as assessed by the Charlson Comorbidity Index21 or by the Cumulative Illness Score Rating-Geriatrics CISR-G,22 should receive attention in the decision making process for active treatment. Other authors advocate the use of a combination of life table data with comorbidity data.23 Apart from these tools, that are of use in all areas of medicine and oncology, also specific nomograms for predicting LE in the setting of PCa have been advocated earlier.24,25 Nevertheless, it has to be taken into account that such nomograms and assessment tools are often complex and require a multitude of inputs, that are not always readily available for clinicians at the time of consultation. Furthermore, these tools are—in contrast to life tables—usually not updated regularly and might be based on historic data. Therefore, the power of life tables relies within their availability, contemporaneity and simplicity.

Taken together, we confirmed that German RP treated patients exhibit superior survival compared to the predicted LE of an age-adjusted simulated cohort that is based upon the general German population. However, this statement is only valid for patients who do not bear very aggressive tumor characteristics. The methodology of using Monte Carlo simulation and Markov Chain on life table data is a powerful tool to evaluate the true impact of a specific disease and its treatment on potential life years lost compared to the LE of the general, nation-specific population. It would be interesting to apply this methodology also in other nations and populations, to confirm our findings and to prove if the survival advantage in RP treated patients compared to the underlying population continues to stay in effect.

Our findings have to be interpreted in the context of potential limitations. First, the presented cohort was treated between 1992 and 2007, which may be regarded as a historic cohort. However, the need for a complete 10-year follow-up dictated the patient selection. Second, the superior observed survival of the overall cohort compared to the simulated cohort might be biased by the presence of a high number of patients with favorable cancer characteristics. Third, the lack of consistent and comparable comorbidity data such as the
CCI or the CISR-G precludes further insights in the general health status of our cohort. Finally, German life tables do not account for differences in race/ethnicity when providing age-based life expectancy estimations, therefore, no adjustment for this variable could be performed. However, the same limitation also applies to life tables from other countries with even more distinct heterogeneity regarding race/ethnicity within the general population, such as the United States, Canada, Switzerland, France or South Africa.²⁶⁻²⁸

5 | CONCLUSION

German low- and intermediate risk PCa patients treated with RP can expect a very favorable overall survival, that even exceeds LE predictions. High risk patients’ overall survival aligns with LE predictions, but may also fall below predictions in specific subgroups with distinctly worse tumor characteristics.

ACKNOWLEDGMENTS

Open Access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTERESTS

The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

Conception and design: Christoph Würnschimmel, Pierre I. Karakiewicz, Derya Tilki. Acquisition of data: Christoph Würnschimmel and Derya Tilki. Analysis and interpretation of data: Christoph Würnschimmel and Zhe Tian. Drafting of the manuscript: Christoph Würnschimmel and Derya Tilki. Critical revision: Wenzel, Wang, Huland, Graefen. Statistical analysis: Christoph Würnschimmel and Derya Tilki. Supervision: Derya Tilki.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Christoph Würnschimmel https://orcid.org/0000-0001-7891-4791
Mike Wenzel https://orcid.org/0000-0002-4338-0889

REFERENCES

1. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415-1424.
2. Carioli G, Bertuccio P, Boffetta P, et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol. 2020;31(5):650-658.
3. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011;29(2):235-241.
4. Liu D, Lehmann HP, Frick KD, Carter HB. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. J Urol. 2012;187(4):1241-1246.
5. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243-262.
6. Eurostat: European life expectancy tables (Eurostat, the statistical office of the European Union). Available from: https://ec.europa.eu/eurostat/databrowser/view/demo_milftable/default/table?lang=en. Accessed January 16, 2021.
7. Boehm K, Larcher A, Tian Z, et al. Low other cause mortality rates reflect good patient selection in patients with prostate cancer treated with radical prostatectomy. J Urol. 2016;196(1):82-88.
8. Preisser F, Bandini M, Mazzone E, et al. Validation of the Social Security Administration Life Tables (2004–2014) in localized prostate cancer patients within the surveillance, epidemiology, and end results database. Eur Urol Focus. 2019;5(5):807-814.
9. Michl U, Tennstedt P, Feldmeier L, et al. Nerve-sparing surgery technique, not the preservation of the neurovascular bundles, leads to improved long-term continence rates after radical prostatectomy. Eur Urol. 2016;69(4):584-589.
10. D’Amico AV. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969.
11. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score. A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039-5046.
12. Tilki D, Mandel P, Schlomm T, et al. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. J Urol. 2015;193(6):1970-1975.
13. Statistisches Bundesamt Deutschland: Sterbetafel (Periodensterbetafel) für Deutschland nach Jahren und vollendetem Alter (männlich). Available from: https://www.genesis.destatis.de/genesis/online/?sequenz=tabelleErgebnis&selectionname=12621-0001&sachmerkmal=GES&sachschluessel=GESM#abreadcrumb. Accessed January 16, 2021.
14. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria. 2013. http://www.r-project.org/. Accessed January 16, 2021.
15. Van Hemelrijck M, Folkvord J, Adolfsen J, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016;117(3):507-514.
16. Winter A, Sirri E, Jansen L, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? BJU Int. 2017;119(4):550-559.
17. Human Mortality Database. University of California, Berkeley and Max Planck Institute for Demographic Research (Germany). Available from: https://www.mortality.org. Accessed January 16, 2021.
18. Vaupel JW, Zhang Z, van Raalte AA. Life expectancy and disparity: an international comparison of life table data. BMJ Open. 2011;1(1):e000128.
19. S3-Leitlinie Prostatakazinom (Version 5.1, 2019), Deutsche Krebsgesellschaft. Available from: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostata_5_001_Prostatakazinom_Langversion_5.1.pdf. Accessed January 16, 2021.
20. Boyle HJ, Alihabsi S, Decoster L, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116-136.
21. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
22. Groome PA, Rohland SL, Siemens DR, Brundage MD, Heaton J, Mackillop WJ. Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates. *Cancer*. 2011;117(17):3943-3952.

23. Mariotto AB, Wang Z, Klabunde CN, Cho H, Das B, Feuer EJ. Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients. *J Clin Epidemiol*. 2013;66(12):1376-1385.

24. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. *J Clin Oncol*. 2007;25(24):3576-3581.

25. Cowen ME, Halasyamani LK, Kattan MW. Predicting life expectancy in men with clinically localized prostate cancer. *J Urol*. 2006;175(1):99-103.

26. Social Security Administration: Actuarial Life Tables (Period Life Table, 2017). Available from: https://www.ssa.gov/. Accessed March 31, 2021.

27. Swiss Federal Statistical Office Life Tables (Sterbetafeln der Schweiz, Schweizerisches Bundesamt für Statistik). Available from: https://www.bfs.admin.ch/. Accessed March 31, 2021.

28. Institute for Health Metrics and Evaluation (IHME); Global Burden of Disease Study 2019 (GBD 2019) Data Resources. Available from: http://ghdx.healthdata.org/gbd-2019. Accessed March 31, 2021.

**SUPPORTING INFORMATION**

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Würnschimmel C, Wenzel M, Wang N, et al. Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data. *The Prostate*. 2021;81:785-793. https://doi.org/10.1002/pros.24176